Erdheim-Chester Disease Clinical Trials

8 recruitingLast updated: June 17, 2026

There are 8 actively recruiting erdheim-chester disease clinical trials across 11 countries. Studies span Phase 2, Early Phase 1, Phase 1, Phase 3. Top locations include New York, New York, United States, Rochester, Minnesota, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Erdheim-Chester Disease Trials at a Glance

8 actively recruiting trials for erdheim-chester disease are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in New York, Rochester, and Boston. Lead sponsors running erdheim-chester disease studies include Memorial Sloan Kettering Cancer Center, Mayo Clinic, and Carl Allen.

Browse erdheim-chester disease trials by phase

Treatments under study

About Erdheim-Chester Disease Clinical Trials

Looking for clinical trials for Erdheim-Chester Disease? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Erdheim-Chester Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Erdheim-Chester Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Histiocytic Disorder Follow-up Study

HistiocytosisErdheim-Chester DiseaseRosai Dorfman Disease+3 more
University of Alabama at Birmingham6,000 enrolled1 locationNCT05915208
Recruiting

ECD-Score: a Study on Erdheim-Chester Disease

Erdheim-Chester Disease (ECD)
Meyer Children's Hospital IRCCS1,000 enrolled7 locationsNCT07454343
Recruiting
Early Phase 1

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Non-Hodgkin LymphomaMultiple MyelomaErdheim-Chester Disease+2 more
Memorial Sloan Kettering Cancer Center30 enrolled1 locationNCT05093335
Recruiting

Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses

Erdheim-Chester Disease
Memorial Sloan Kettering Cancer Center500 enrolled1 locationNCT03329274
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

MelanomaCarcinoma, Non-Small Cell LungOvarian Neoplasms+9 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 2

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more
Carl Allen90 enrolled12 locationsNCT04079179
Recruiting

International Rare Histiocytic Disorders Registry (IRHDR)

Rare Histiocytic Disorders (RHDs)Erdheim-Chester Disease (ECD)Rosai-Dorfman Disease (RDD)+7 more
The Hospital for Sick Children400 enrolled15 locationsNCT02285582